[go: up one dir, main page]

JO3691B1 - سترويدات وتركيبات نشطة عصبياً، واستخداماتها - Google Patents

سترويدات وتركيبات نشطة عصبياً، واستخداماتها

Info

Publication number
JO3691B1
JO3691B1 JOP/2015/0132A JOP20150132A JO3691B1 JO 3691 B1 JO3691 B1 JO 3691B1 JO P20150132 A JOP20150132 A JO P20150132A JO 3691 B1 JO3691 B1 JO 3691B1
Authority
JO
Jordan
Prior art keywords
disorders
present application
treatment
range
compositions
Prior art date
Application number
JOP/2015/0132A
Other languages
English (en)
Inventor
G Salituro Francesco
Thomas Beresis Richard
L Harrison Boyd
Jean Robichaud Albert
Martinez Botella Gabriel
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Application granted granted Critical
Publication of JO3691B1 publication Critical patent/JO3691B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم في الطلب الحالي 19-نور C3, 3-سترويدات ليس بها استبدال لها الصيغة (I): (I) وأملاح منها مقبولة صيدلانياً; حيث R1، R2، R3، وR4 تكون وفقاً لما تم تعريفه في الطلب الحالي، وA تكون نظام حلقة أريل غير متجانسة يشتمل على 3 أو 4 ذرات نيتروجين وفقاً لما تم تعريفه في الطلب الحالي. من المتوقع أن تكون مثل هذه المركبات مفيدة للوقاية من وعلاج مجموعة من الحالات المتعلقة بـ CNS، على سبيل المثال، علاج اضطرابات النمو، اضطرابات المزاج، اضطرابات نطاق انفصام الشخصية، اضطرابات تشنج، اضطرابات الذاكرة و/أو الإدراك، اضطرابات الحركة، اضطرابات الشخصية، اضطراب أنواع التوحد، ألم، إصابة مخ رضحية، أمراض أوعية دموية، اضطرابات إدمان المخدرات و/ أو متلازمات الانسحاب، وطنين الأذن.
JOP/2015/0132A 2014-05-29 2015-05-31 سترويدات وتركيبات نشطة عصبياً، واستخداماتها JO3691B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014078820 2014-05-29
PCT/CN2015/080216 WO2015180679A1 (en) 2014-05-29 2015-05-29 Neuroactive steroids, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
JO3691B1 true JO3691B1 (ar) 2020-08-27

Family

ID=54698130

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0132A JO3691B1 (ar) 2014-05-29 2015-05-31 سترويدات وتركيبات نشطة عصبياً، واستخداماتها

Country Status (27)

Country Link
US (5) US20180179247A1 (ar)
EP (3) EP3705488B1 (ar)
JP (4) JP6652934B2 (ar)
KR (3) KR102664412B1 (ar)
CN (3) CN114133423A (ar)
AR (2) AR100691A1 (ar)
AU (4) AU2015266447A1 (ar)
CA (1) CA2949720C (ar)
CY (1) CY1124109T1 (ar)
DK (2) DK3149018T3 (ar)
ES (2) ES2927007T3 (ar)
HR (2) HRP20201126T1 (ar)
HU (2) HUE050028T2 (ar)
IL (3) IL304033A (ar)
JO (1) JO3691B1 (ar)
LT (2) LT3149018T (ar)
MX (5) MX394493B (ar)
PH (2) PH12021550762A1 (ar)
PL (2) PL3149018T3 (ar)
PT (2) PT3705488T (ar)
RS (2) RS63554B1 (ar)
RU (2) RU2019126637A (ar)
SG (2) SG11201609813XA (ar)
SI (2) SI3705488T1 (ar)
SM (2) SMT202000406T1 (ar)
TW (3) TW202426001A (ar)
WO (1) WO2015180679A1 (ar)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
PT2766380T (pt) 2011-10-14 2019-07-29 Sage Therapeutics Inc Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
KR102614507B1 (ko) 2013-04-17 2023-12-19 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
PL2986624T3 (pl) 2013-04-17 2020-11-16 Sage Therapeutics, Inc. Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia
CA3199003A1 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HUE052308T2 (hu) 2013-08-23 2021-04-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
ES2927007T3 (es) * 2014-05-29 2022-10-31 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3206493B1 (en) 2014-10-16 2020-05-06 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN117024502A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
AU2017229656B2 (en) * 2016-03-08 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017296295B2 (en) * 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
KR20230079470A (ko) 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
EP3728284B1 (en) * 2017-12-22 2024-08-21 Sage Therapeutics, Inc. 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
CN114805462B (zh) * 2018-02-11 2024-06-18 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP3911331A4 (en) * 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
US20220275020A1 (en) 2019-08-07 2022-09-01 Shanghai Hansoh Biomedical Co., Ltd. Salt and crystal form of steroid derivative regulator
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
JP2024507638A (ja) * 2021-01-28 2024-02-21 セージ セラピューティクス， インコーポレイテッド 性機能障害処置のための神経刺激性ステロイドの使用
KR20240037975A (ko) * 2021-07-28 2024-03-22 세이지 테라퓨틱스, 인크. 신경활성 스테로이드의 결정질 형태
WO2023164387A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
WO2024189061A1 (en) 2023-03-14 2024-09-19 Curia Spain, S.A.U. Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids
CN120917034A (zh) * 2023-05-11 2025-11-07 上海枢境生物科技有限公司 甾体类化合物、制备方法及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634717A1 (de) * 1986-10-11 1988-04-14 Dynamit Nobel Ag Verfahren zur herstellung von 5-methyltetrazol
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
FR2679263B1 (fr) 1991-07-15 1994-01-14 Staubli Ets Perfectionnements aux ratieres a double leve du type hattersley pour machines a tisser.
BR9506779A (pt) * 1994-02-14 1997-10-14 Cocensys Inc Composto composição farmacéutica método para modular o complexo ionóforo receptor gaba-cloreto em um paciente animal pela ligação ao sitio neuroesteróide no dito complexo método para tratar ou evitar estresse ou ansiedade em um paciente animal método para aliviar ou evitar isônia pms ou pnd em um paciente animal método para tratar ou evitar perturbacões na disposicão de ánimo em um paciente animal e método para induzir anestesia em um paciente animal
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
YU77701A (sh) * 1999-04-29 2005-07-19 Euro-Celtique S.A. 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
WO2004036372A2 (en) * 2002-10-15 2004-04-29 Medtronic Inc. Scoring of sensed neurological signals for use with a medical device system
US7729773B2 (en) * 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
PT2766380T (pt) * 2011-10-14 2019-07-29 Sage Therapeutics Inc Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
ES2927007T3 (es) * 2014-05-29 2022-10-31 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
EP3206493B1 (en) * 2014-10-16 2020-05-06 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
MX2016015532A (es) 2017-02-27
AR100691A1 (es) 2016-10-26
US20210061850A1 (en) 2021-03-04
WO2015180679A1 (en) 2015-12-03
US20180179247A1 (en) 2018-06-28
EP3149018A4 (en) 2017-12-06
IL304033A (en) 2023-08-01
JP2021130696A (ja) 2021-09-09
JP2023123878A (ja) 2023-09-05
PL3705488T3 (pl) 2022-12-05
MX382131B (es) 2025-03-13
DK3149018T3 (da) 2020-07-20
US20210061849A1 (en) 2021-03-04
RU2699359C2 (ru) 2019-09-05
SG11201609813XA (en) 2016-12-29
NZ764921A (en) 2023-11-24
AU2021204410A1 (en) 2021-07-22
MX2023004352A (es) 2023-05-08
CY1124109T1 (el) 2022-03-24
SMT202000406T1 (it) 2020-09-10
JP6892936B2 (ja) 2021-06-23
AU2023285755A1 (en) 2024-01-18
TW201625661A (zh) 2016-07-16
US20240076310A1 (en) 2024-03-07
RU2016151727A (ru) 2018-07-02
LT3149018T (lt) 2020-08-10
IL248948B (en) 2022-09-01
SMT202200416T1 (it) 2022-11-18
MX2021005099A (es) 2021-06-15
JP2017516793A (ja) 2017-06-22
PT3705488T (pt) 2022-09-30
CA2949720A1 (en) 2015-12-03
PL3149018T3 (pl) 2021-01-25
RS63554B1 (sr) 2022-09-30
AU2015266447A1 (en) 2016-12-01
JP2020073577A (ja) 2020-05-14
AU2019279910A1 (en) 2020-01-16
PT3149018T (pt) 2020-07-21
NZ726260A (en) 2023-11-24
MX2021005106A (es) 2021-06-15
AR121661A2 (es) 2022-06-29
JP6652934B2 (ja) 2020-02-26
ES2805598T3 (es) 2021-02-12
IL292461B1 (en) 2023-11-01
HUE059829T2 (hu) 2022-12-28
CA2949720C (en) 2025-11-18
KR102494061B1 (ko) 2023-01-31
TWI839649B (zh) 2024-04-21
JP7386204B2 (ja) 2023-11-24
SI3705488T1 (sl) 2022-10-28
US20200165291A1 (en) 2020-05-28
NZ764941A (en) 2023-11-24
RU2019126637A (ru) 2019-10-03
KR102664412B1 (ko) 2024-05-21
AU2021204410B2 (en) 2023-09-21
RU2016151727A3 (ar) 2018-12-03
HRP20201126T1 (hr) 2020-12-11
SG10201803812TA (en) 2018-06-28
EP4144746A1 (en) 2023-03-08
PH12021550762A1 (en) 2023-07-17
CN106661078A (zh) 2017-05-10
TW202231652A (zh) 2022-08-16
MX394493B (es) 2025-03-24
IL292461B2 (en) 2024-03-01
EP3705488A1 (en) 2020-09-09
PH12016502342A1 (en) 2017-02-13
SI3149018T1 (sl) 2020-10-30
IL248948A0 (en) 2017-01-31
LT3705488T (lt) 2022-09-26
KR20230021165A (ko) 2023-02-13
CN114133423A (zh) 2022-03-04
EP3149018A1 (en) 2017-04-05
BR112016027508A2 (pt) 2018-06-26
KR20240066304A (ko) 2024-05-14
DK3705488T3 (da) 2022-10-03
KR20170003706A (ko) 2017-01-09
EP3149018B1 (en) 2020-04-29
ES2927007T3 (es) 2022-10-31
EP3705488B1 (en) 2022-08-03
AU2019279910B2 (en) 2021-07-22
IL292461A (en) 2022-06-01
HRP20221294T1 (hr) 2023-03-03
TW202426001A (zh) 2024-07-01
RS60529B1 (sr) 2020-08-31
HUE050028T2 (hu) 2021-12-28
CN114369135A (zh) 2022-04-19

Similar Documents

Publication Publication Date Title
JO3691B1 (ar) سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CY1124175T1 (el) Νευροδραστικα στεροειδη 19-nor για μεθοδους θεραπευτικης αντιμετωπισης
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
MX395023B (es) Esteroides c21-n-pirazolilo 19-nor c3,3-disustituidos y metodos de uso de los mismos.
AR108012A1 (es) Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl
MX373274B (es) Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer.
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
TW201612158A (en) Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof
JO3146B1 (ar) مشتقات غير متجانسة الحلقية و استخدامها في علاج الاضطرابات العصبية
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
CL2018000241A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
EA201690790A1 (ru) Серосодержащее бициклическое соединение
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
EA201692264A1 (ru) Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2019007103A (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201890769A1 (ru) Производные 2,3,4,5-тетрагидропиридин-6-амина